

Collaborative **Working Project Executive Summary**

Published on <https://www.fresenius-kabi.com/gb/>

Improving Patient Outcomes In Moderate RA – Implementing TA715 At Bedfordshire Hospitals NHS Foundation Trust

Project description:

In July 2021, NICE published a Technology Appraisal Guidance document (TA715), that included patients defined as having moderate disease in Rheumatoid Arthritis to be eligible for Anti-Tumour Necrosis Factor (anti-TNF) therapies. This joint working project will set up a dedicated service at Bedfordshire Hospitals NHS Foundation Trust to review and identify patients diagnosed with moderate rheumatoid arthritis who may benefit from an anti-TNF, thus ensuring that these patients would receive optimal treatment and management in line with current NICE TA715 guidance.

Organisations involved:

Fresenius-Kabi and Bedfordshire Hospitals NHS Trust have contributed resources to this project.

Clinical efficacy and safety outcomes will be measured during this Joint Working Project.

Benefits to Patients:

- Earlier access to anti-TNF therapy than if the service had not been set up
- Potential for improved clinical outcomes for these moderate rheumatoid arthritis patients as a result of receiving anti-TNF therapy earlier on in the course of their disease

Benefits to Bedfordshire Hospitals NHS Trust

- Reviewing all moderate rheumatoid arthritis patients will ensure they are on the most cost-effective and efficacious treatment for their stage of disease.
- Potential to reduce pressure on the rheumatology service at the Trust as treating moderate disease earlier with anti-TNFs may reduce incidence of disease flare-ups and return appointments.

Benefits to Fresenius-Kabi

- Correct identification of patients with moderate rheumatoid arthritis disease, with increased capacity for delivery of appropriate approved treatments of which Fresenius-Kabi has one.

- Demonstrating that Fresenius Kabi is able to work in partnership with an NHS Trust to support and implement national guidance to improve patient access to optimal therapy and management.

Start Date: Q4 2022